Company news
Endra Life Sciences Inc. (NASDAQ:NDRA) news
Every Endra Life Sciences Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
ENDRA Life Sciences Reports Second Quarter 2026 Financial Results and Provides Business Update
August 17, 2026
ASP Isotopes Announces Proposed Merger of Noble Africa with ENDRA Life Sciences and Approximately $50 Million Concurrent Private Placemen...
June 25, 2026
ENDRA Life Sciences Reports First Quarter 2026 Financial Results and Provides Business Update
May 18, 2026
ENDRA Life Sciences Reports Multi-Site Validation of TAEUS® Liver Device Demonstrating MRI-like Accuracy and Reproducibility
May 14, 2026
ENDRA Life Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
March 31, 2026
ENDRA Life Sciences Initiates Review of Strategic Alternatives to Maximize Shareholder Value
March 25, 2026
ENDRA’s TAEUS® Liver Device Demonstrates High-Level Consistency in Clinical Study, Delivering MRI-Level Results at the Point of Patient Care
February 26, 2026
ENDRA’s TAEUS® Liver Matches MRI-PDFF Performance at Key Clinical Thresholds, Positioning Device for MASLD/MASH Trial Use
December 4, 2025
ENDRA Feasibility Study Demonstrates TAEUS® Accurately Quantifies Liver Fat Fraction, a Key MASLD/MASH Biomarker
November 20, 2025
ENDRA Life Sciences Recaps Major Milestones and New Strategic Initiatives, Announces Third Quarter 2025 Financial Results
November 17, 2025
ENDRA Life Sciences Commences Staking of HYPE Digital Asset Holdings, Reinforcing Long-Term Strategy with Anchorage Digital and ARCA
November 13, 2025
ENDRA Life Sciences Closes Up to $14.4 Million Private Placement and Launches Crypto Treasury Strategy with $3 Million in Initial HYPE To...
October 23, 2025
ENDRA Life Sciences Announces At-Market Private Placement of Up to $14.4 Million to Launch Digital Asset Treasury Strategy Managed by Lea...
October 13, 2025
ENDRA Life Sciences Provides a Business Update and Reports Second Quarter 2025 Financial Results
August 14, 2025
ENDRA’s Ongoing Multisite Pilot Study Reveals Important Enhancements to Boost TAEUS Liver Accuracy and Repeatability Against MRI Gold Sta...
June 16, 2025
ENDRA Life Sciences Provides a Business Update and Reports First Quarter 2025 Financial Results
May 15, 2025
ENDRA Life Sciences Announces Enhanced Strategy to Enable the Early Detection and Management of Metabolic Diseases Facilitated by Emergin...
March 31, 2025
ENDRA Life Sciences Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides a Business Update
March 31, 2025
ENDRA Life Sciences Regains Compliance with Nasdaq Minimum Bid Price Requirement
November 22, 2024
ENDRA Life Sciences Reports Third Quarter 2024 Financial Results and Provides a Business Update
November 15, 2024
ENDRA Life Sciences Further Strengthens TAEUS® Platform Intellectual Property with Issuance of 17th European Patent
November 6, 2024
ENDRA Life Sciences Activates TAEUS System to Initiate Clinical Study at LMU University Hospital in Germany
October 22, 2024
ENDRA Life Sciences Granted Extension to Regain Compliance with Nasdaq Continued Listing Requirements
August 28, 2024
ENDRA Life Sciences Reports Second Quarter 2024 Financial Results and Provides a Business Update
August 22, 2024
ENDRA Life Sciences Announces Reverse Stock Split
August 16, 2024
ENDRA Life Sciences Announces Leadership Changes
August 13, 2024
ENDRA Life Sciences Reschedules Second Quarter Conference Call to August 22, 2024
August 13, 2024
ENDRA Life Sciences Announces Pricing of $8.0 Million Public Offering
June 4, 2024
ENDRA Life Sciences Reports First Quarter 2024 Financial Results and Provides a Business Update
May 14, 2024
ENDRA Life Sciences to Report First Quarter 2024 Financial Results on May 14, 2024
May 7, 2024
ENDRA Life Sciences Strengthens Intellectual Property with Issuance of Five New International Patents
May 2, 2024
ENDRA Life Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
March 28, 2024
ENDRA Life Sciences to Report Fourth Quarter 2023 Financial Results on March 28, 2024
March 21, 2024
ENDRA Life Sciences Installs First TAEUS System in the UK
February 27, 2024
ENDRA Life Sciences Bolsters TAEUS® System Intellectual Property with New Patents in U.S., China and Europe
February 14, 2024
ENDRA Life Sciences Secures 39th U.S. Patent for TAEUS® System Technology
November 29, 2023
ENDRA Life Sciences Reports Third Quarter 2023 Financial Results and Provides Business Update
November 14, 2023
ENDRA Life Sciences Achieves Intellectual Property Milestone with Issuance of Three New Patents
November 8, 2023
ENDRA Life Sciences to Report Third Quarter 2023 Financial Results on November 14, 2023
November 7, 2023
ENDRA Life Sciences' TAEUS De Novo Submission Advances to Next Stage of Review with FDA
August 30, 2023
ENDRA Life Sciences Expands Intellectual Property with Issuance of U.S. and European Patents
August 23, 2023
ENDRA Life Sciences Submits De Novo Request for its TAEUS® System Liver Fat Application to the U.S. FDA
August 14, 2023
ENDRA Life Sciences Reports Second Quarter 2023 Financial Results and Provides a Business Update
August 14, 2023
ENDRA Life Sciences to Report Second Quarter 2023 Financial Results on August 14, 2023
August 1, 2023
ENDRA Life Sciences Reports First Quarter 2023 Financial Results and Provides a Business Update
May 15, 2023
ENDRA Life Sciences to Report First Quarter 2023 Financial Results on May 15, 2023
May 4, 2023
ENDRA Life Sciences Announces Closing of Public Offering and Full Exercise of Underwriter’s Option to Purchase Additional Securities
May 2, 2023
ENDRA Life Sciences Announces Pricing of Upsized $4.5 Million Public Offering
April 28, 2023
ENDRA Life Sciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
March 14, 2023
ENDRA Life Sciences to Report Fourth Quarter and Full Year 2022 Financial Results on March 14, 2023
March 7, 2023